Table 1

Patient demographic characteristics, stratification variables, paclitaxel Css,avg, and disease outcome by treatment arm

Paclitaxel treatment armsaP
PCPCG
No. of patients7571
Median age (range)60.9 (37.9–75.6)59.4 (39.8–76.3)0.9594
ECOG performance status (0:1)28:4324:510.3897
Sex (male:female)47:2447:280.7304
Weight loss (<5%:≥5%)56:1554:210.3457
Disease stage (IIIb:IV)11:6012:631.0000
Css,avg (μmol/liter)b0.32 (0.12–2.7)0.81 (0.11–3.6)<0.0001
Response (CR/PR):(SID/PD)24:4720:550.3719
TTF (months)b5.5 (1.4–27.0)5.1 (0.62–31.6)0.6201
Survival (months)b11.3 (2.4–32)11.6 (1.6–33)0.7173
  • a Treatment arms: PC, 75 mg/m2 cisplatin i.v. on day 2 preceded by 135 mg/m2 paclitaxel over 24 h i.v. on day 1; PCG, 75 mg/m2 i.v. cisplatin on day 2 preceded by 250 mg/m2 paclitaxel i.v. over 24 h on day 1 plus 5 μg/kg G-CSF starting on day 3.

  • b Values represent median (range).